Performance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data – a database study in the British population

Use of imputation methods enabled us to use the EndPAC score for all NOD patients. However, use of the EndPAC score alone is still not sufficient to select NOD patients for diagnostic workup, with or without complete information. Its use in combination with a biomarker might lead to a better risk-benefit ratio.